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SUMMARY
The thesis reports studies on patients with 
epilepsy. The effects of two newly introduced anti­
convulsant agents are discussed with regard to the 
seizure control, side effects, serum levels and their 
effect on the metabolism of other anticonvulsant drugs 
when used in combination. Some of the metabolic changes 
induced by anticonvulsant medication are reported. *
The introduction to the thesis gives an account 
of the general mode of action of anticonvulsant drugs, 
and indicates the continual search for the ideal anti­
convulsant. The methods used in various analyses in 
this thesis are described.
The thesis is then divided into two sections. The 
first deals with the comparative trial of the two newly 
introduced anticonvulsant agents, i.e. sodium valproate 
(EPILIM) and clonazepam (RIVOTRIL). The two drugs were 
studied in a cross-over trial in chronic epileptic 
patients who were showing poor control; one of the 
trial drugs was added to the existing therapy for a 
period of 12 weeks, after which the patients took the 
second drug. Sodium valproate was the more effective 
drug with the least side effects. However, sodium val­
proate had more effect on other serum anticonvulsant 
drug levels: it increased the serum levels of pheno­
barbitone and reduced those of phenytoin in some patients
T h e / . . .
The second section of the thesis deals with two 
of the changes in metabolism induced by the chronic 
intake of anticonvulsant drugs. Chapters 3, 4 and 5 
deal with the incidence of serum IgA depletion, the 
effect of anticonvulsants on secretory IgA, the relation 
of serum IgA depletion to the HLA status, and the effect 
anticonvulsants have on lymphocyte protein synthesis.
The results show that roughly one fourth of the patients 
studied had reduced serum IgA levels, and this directly 
related to the intake of phenytoin. The reduction in 
serum IgA was not found to be reflected on the active 
form of IgA, viz, secretory IgA; although found to be 
reduced, this was to a much lesser degree than that of 
the serum. The reduction in serum IgA in patients on 
phenytoin was related to the higher incidence of a 
specific HLA pattern in these patients. HLA-A2 was 
much more prevalent in these patients than in patients 
on the same medication but who did not have a low serum 
IgA level. Lymphocyte protein synthesis was found to be 
reduced in all patients on anticonvulsants when compared 
to controls.
During the IgA studies serum folate was measured, 
and it was found to be reduced in 90% of the patients. 
This was further studied in Chapters 7 and 8. Serum 
folate was found to be reduced in most of the patients 
studied. Those who had the lowest serum folate levels 
had CSF examination for folate, which was found to be 
reduced/...
XX
reduced as well. The effects of treating patients with 
low serum and CSF folate is reported. The treatment 
v/as with folic acid or with 5-formyltetrahydrofolate.
The effects of treatment on seizure frequency, serum 
anticonvulsant levels and CSF amine metabolites (HVA 
and HIAA) were studied. The results show that CSF folate 
increased more with 5“formyltetrahydrofolate treatment. 
Serum phenytoin levels were reduced with treatment, and 
the levels of HVA and HIAA were reduced with 5-formyl- 
tetrahydrofolateÎ there was, however, no effect on 
seizure frequency.
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UNITS USED
Kg
rag
ug
ml
dl
}il
pmol/1 
nmol/I
kilogram 1 x lO-’ gram
milligram 1 x 10“"^  gram 
microgram 1 x 10'"^  gram
millilitre 1 x 10™^ litre
decilitre 1 x 10“  ^litre
microlitre 1 x 10“"^  litre
micromoles per litre 1 x 10™ moles per 
litre
nanomoles per litre 1 x 10 ^ moles per 
litre
min minute
oc degree centigrade
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ABBREVIATIONS
A.I.P.
CSF
DNA
EEG
GABA
HIAA
HLA
HVA
IgA
IgG
IgM
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phenytoin
R.I.D.
RNA
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SD
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Histocompatibility lymphocyte antigen
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Ribonucleic acid
ter in diem
Standard deviation
1.
INTRODUCTION
Epilepsy affects one in 200 of the population (Brain 
and Walton, 1969). In two-thirds of all patients, it 
takes a chronic form and consequently patients continue 
taking anticonvulsants. This makes anticonvulsant drugs 
one of the most commonly taken drugs. Because of the 
large number of anticonvulsant drugs which are only 
effective in certain types of epilepsy, a large percent­
age of medical practitioners still have difficulties 
in choosing the right drug and dosage for their patients. 
In this thesis, the effects of new drugs introduced into 
the armamentarium of anticonvulsant agents,and some of 
the effects on metabolism produced by anticonvulsants 
are studied.
Modern concepts about epilepsy were started by the 
eminent neurologist Hughling Jackson in the 19th century. 
He postulated that epilepsy is an intermittent disorder 
of the nervous system due presumably to a sudden, excess­
ive, disorderly discharge of cerebral neurons.
The problem of treating seizures is still far from 
ideal. This is mainly because we are still not treating 
the original defect causing the seizures, but mainly 
trying to stop the propagation of the * disorderly dis­
charge*. Anticonvulsant drug therapy is only one pillar 
in the management of the epileptic patient.
Any/...
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Any general depressant of the nervous system will 
diminish or stop epileptic activity. Anticonvulsants 
act mainly by preventing the spread of the discharge 
from an epileptic focus. There are many possible ways 
in which anticonvulsants might operate to abolish or 
attenuate seizures:
1, Effects on non-neural lesions, such as
*
normalisation of the ischaemic blood supply of an 
epileptic focus; however, it is notable that autonomic 
blocking or facilitating agents have little or no value 
in the treatment of epilepsy.
2, Effects confined to the pathologically altered 
neurons of the seizure focus, to prevent their excessive 
discharge; such an action is suspected, but not proved 
in the ability of increased blood levels of COg to 
abolish clinical petit mal seizures.
3, Effects on normal neurons to prevent the 
detonation by the seizure focus. This probably includes 
most if not all the presently available anticonvulsant 
drugs; all can be demonstrated to modify the ability of 
the brain to respond to various seizure evoking stimuli. 
The particular physiological effects might include 
reduction of post-tetanic potentiation, elevation of 
excitatory synaptic threshold, potentiation of either 
pre-synaptic or post-synaptic inhibition, and prolongation 
of/...
of the refractory period.
The ideal anticonvulsant
The ideal anti-epileptic agent should be capable 
of suppressing seizures at a dosage that does not lead 
to sedation or other central toxicity, it should be well- 
tolerated by the oral route, should not lead to tolerance 
or withdrawal symptoms, should be cheap, long-acting, 
devoid of systemic toxic effects and free from even 
occasional idiosyncratic effects. The drug should 
preferably have a wide margin of safety, with a wide 
range of activity to control all types of clinical 
epilepsy through exerting its effects directly on the 
seizure focus (Toman, 1970). No such drug exists or is
likely to be discovered for some time.
(
Various anticonvulsant drugs have been introduced 
mainly since the beginning of this century. After the 
use of Bromide since 1857, the first of the modern anti­
convulsant agents was introduced, i.e. Barbiturate 
derivatives. In 1905 Barbitone and in 1912 phenobarbi­
tone were introduced. In 1938 after an intensive search, 
Diphenylhydantoin (phenytoin) was introduced by Merrit 
and Putnam. Since then, several other anticonvulsants 
have been introduced. However, the two most commonly 
used anticonvulsant agents today are still phenytoin and 
phenobarbitone/...
4.
phenobarbitone.
To measure the therapeutic and the side effects 
of an anticonvulsant involves reliable seizure recording, 
good compliance (which is best monitored by serum 
levels), avoidance of contributory factors, knowledge 
of the pharmacokinetics of the drug, and lastly giving 
enough time for observation. In the work reported in 
this thesis, these criteria were to a very large esftent 
adhered to.
This thesis is divided into two sections; the 
first deals with the effects of two anticonvulsant drugs, 
namely sodium valproate and clonazepam. Sodium valproate 
(Di-propylacetate; EPILIM, Reckitt and Colman) is a newly 
introduced drug in this country, and a lot of its 
properties are still not worked up. The drug is derived 
from a fatty acid with a different mode of action when 
compared to other anticonvulsants in use. The postulated 
mode of action of sodium valproate is through increasing 
the levels of gamma-amino butyric acid (GABA) by 
inhibiting GABA transaminase. The brain concentration 
of GABA has been shown to increase following the admin­
istration of certain anticonvulsants, and its concentra­
tion has been shovm to be reduced following certain 
convulsants (Meldrum, 1975). Sodium valproate has been 
shown to increase the levels of GABA in both the cerebral 
cortex/...
cortex and the cerebellum, with complete protection 
against audiogenic seizures (Ciesielski, Maitre, Cash 
and Mandel, 1975). The effectiveness of sodium valproate, 
when added to other drugs, has been shown by previous 
workers (Jeavons and Clark, 1974; Richens and Ahmed, 1975)
The other drug which is reported in this thesis is
clonazepam (RIVOTRIL, Roche Products), It is a benzo-
*
diazepine and its effectiveness and side effects are 
still being assessed (Nanda,'Keogh, Lambie, Johnson, 
Melville and Morrice, 1976), It was felt that a com­
parative trial of the effects of both drugs on seizure 
frequency, anticonvulsant serum levels and toxicity was 
needed. This will be reported upon in Section 1 of this 
thesis.
Patients who take drugs for life present a unique 
opportunity to study various aspects of metabolism, which 
may be changed due to direct or indirect effect of the 
drug intake. Anticonvulsants affect the immune system, 
particularly Immunoglobulin A (IgA); this has been 
shown to be reduced, as well as lymphocyte protein syn­
thesis (Sorrell and Forbes, 1975), Another immuno­
globulin, namely IgG, was reported to be involved, and 
the serum IgA depletion was not correlated with phenytoin 
therapy (Slavin, Fenton, Laundy and Reynolds, 1974). IgA 
function is that of protecting the mucous membranes and 
it/.,.
it is secreted by plasma cells in the submucous layer 
of the raucous membranes, IgA is found in nearly all 
body secretions (Walker and Isselbacher, 1977). The 
secretory IgA is the functional form, and it has been 
reported to be reduced in epileptic patients on anti­
convulsants (Aarli and Tonder, 1975). However, this 
may not be the case because serum and secretory IgA 
levels do not necessarily follow the same pattern » 
(Tomasi, 1968), The cause of the serum IgA deficiency 
is not known, but there,is a suggestion that it could 
be genetic (Fontana, Grob, Sauter and Joller, 1976),
The serum and salivary IgA status will be reported upon 
in Chapters 3» 4 and 5 of this thesis in relation to 
anticonvulsant intake and drug levels, folate status, 
and HLA typing. In addition, lymphocyte protein syn­
thesis as a marker of T-cell function is also studied.
The other aspect of metabolism studied in this thesis 
is that of folate. It is well known that anticonvulsants 
produce changes in the folate metabolism. This was 
reported as increased incidence of macrocytosis (Hawkins 
and Meynell, 1958). Several other workers since have 
assessed the effect of anticonvulsant drugs on folic 
acid metabolism. Cerebrospinal fluid (CSF) folate is 
normally higher than that of the serum (Wells and Casey, 
1967). This was reported to be reduced also in epileptic 
patients/...
7patients on anticonvulsants (Reynolds, Mattson and 
Gallagher, 1972). The CSF levels of folate were 
reported only to increase when the reduced form of 
folic acid (5-formyltetrahydrofolate) was used for 
treatment, and not with folic acid itself, indicating 
perhaps that anticonvulsants interfere with the conver­
sion of folic acid into the active form, i.e. 5-methyl- 
tetrahydrofolate (Mattson, Gallagher, Reynolds and »
Glass, 1973). The effects of treating folate deficient 
epileptic patients has been controversial as regards 
their mental state and seizure frequency. Worsening of 
seizure frequency has been reported (Reynolds and Wales, 
1967). However, this was not confirmed by other workers 
(Jensen and Olesen, 1970), The amine metabolites in the 
CSF, namely 5-hydroxy-3-indole acetic acid (HIAA) and 
homovanillic acid (HVA) have been reported to be increased 
in epileptic patients (Chadwick, Jenner and Reynolds, 
1975). The relation of this finding to folate metabolism 
is uncertain, and it is controversial whether folate acts 
as a methyl donor in amine metabolism (Reynolds, Chadwick, 
Jenner and Chanarin, 1975). Administration of folic 
acid to epileptic patients did not significantly lower 
the CSF HVA or HIAA (Hunter, Barnes, Curzon, Kantamaneni 
and Duncan, 1971),
The effects of treatment of folate deficient 
epileptic patients with either folio acid or 5-formyl- 
tetra/...
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tetrahydrofolate in relation to CSF folate, and with 
particular reference to CSF amine metabolites, is 
reported in Chapters 6 and 7.
9.
METHODS
PATIENTS
The studies reported in this thesis were done on
patients suffering from various types of epilepsy.
They were mainly patients from the Epilepsy Centre,
Quarrier*s Homes, Bridge of Weir, Renfrewshire, and some*
patients attending the Institute of Neurological Sciences, 
Southern General Hospital, Glasgow. The number of 
patients and the particular type of epilepsy will be 
given in each chapter as they were included in various 
studies,
TECHNIQUES
/
a) Blood sampling
Blood samples were taken by venepuncture from an 
antecubital vein after cleaning the area with spirit.
If serum anticonvulsants were to be measured, the 
patients would be fasted overnight, but in the case of 
anticonvulsants with a short half life, i.e. primidone 
and sodium valproate, the blood samples were taken two 
hours after the morning dose. Blood was collected in 
plain plastic tubes. The serum was separated and stored 
at “20^C until the time of assay.
b/...
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b) Cerebrospinal fluid sampling
Cerebrospinal fluid (CSF) samples were taken in 
the morning in fasting patients. The patients were kept 
lying in bed after awakening in the morning and lumbar 
puncture was performed using gauge 20 lumbar puncture 
needles while the patients were in the left lateral 
position. The skin was cleaned with Hibitane and the 
disc space identified. Local anaesthesia in the foç*m 
of Lignocaine 2% was infiltrated before inserting the 
spinal needle. Around 8 mis of CSF was collected in two 
separate containers. The first 5 mis were used for HVA 
and HIAA assay, and the rest for CSF folate. The 
samples were stored at -200C until they were analysed,
c) Parotid saliva sampling
Sampling from one of the parotid duct openings 
was done in the morning after an overnight fast, and 
following a mouth-rinse with water. The•saliva was not 
stimulated. It was collected using a modified Carlson- 
Crittenden collecting cup (Schaeffer, Sproles and Krakov/ski 
1973),' This cup consists of two rounded compartments, 
one inside the other, each connected to the outside by 
a separate tubing. The inner one is applied over the 
parotid duct opening and the outer one is connected to 
continuous suction. Saliva is collected through the 
tubing that comes from the inner ring (Fig. i). Around 
1 ml of unstimulated parotid saliva was collected over 
30/...
Fig. i Carlson-Crittenden cup, for collecting parotid 
saliva. The saliva accumulates in the inner 
compartment, and continuous suction is applied 
to the outer compartment.

1 1 .
30 - 43 min and stored at -20®C until the time of 
analysis.
The biological fluids were examined by a series 
of techniques for analyses of anticonvulsants, immuno­
globulins, folates, catecholamine and serotonin meta­
bolites, I was helped in some of the techniques as part 
of this work was a collaboration with certain colleagues, 
to whom I am grateful. Details of the assays are given 
below,
ASSAYS
a) Anticonvulsant drug assays
Phenytoin, phenobarbixone and primidone were 
measured by gas-liquid chromatography using a Pye Unicam 
gas chromatograph (Type 104)equipped with dual flame 
ionization detectors. Separation was achieved by 
temperature programming on a 3 ft. (91.44 cm) glass column 
of OVI (80-100 mesh), Pye Unicam Ltd. The method used is a 
variation of that described by Goudie and Burnett (1973) 
using p-tolyl phenylhydantoin as internal standard and 
on column méthylation with trimethylphenyl ammonium 
hydroxide.
Sodium valproate was estimated by an isothermal gas 
liquid chromatographic method using a 3 ft. (91.44 cm) 
column of 2% WG/11 on Chromosorb ¥ (HP) 80-100 mesh. The 
method is as follows:- pipette 100 pi serum, 50 pi internal 
standard/...
1 2 .
standard solution (200 mg% cyclohexane carboxylic acid in 
1 N H2SO4), and 100 pl Dichloromethane into a 5 ml conical 
tube; vortex 30 seconds, centrifuge. If organic layer 
remains cloudy stir with fine wire and re-centrifuge.
Draw about 1 pl air into 5 pl syringe and place needle 
in organic layer (no need to remove upper layer), eject 
air and draw in 2-3 pl lower layer for GLC. The oven 
temperature was 150^0 and the detector block temperature 
v/as 250^0. The carrier gas used was oxygen-free nitrogen 
(B.O.C, Ltd.) at a flow rate of 30 ml/rain.
Clonazepam was measured by radio-immunoassay 
(0*Kelly, 1975) at the Psycho-endocrine Research Centre,
St. James Hospital, Dublin.
The techniques using the gas chromatograph were all 
in operation in the laboratory when I joined it. I 
became proficient in the techniques and many of the results * 
therefore depend upon assays carried out by me.
b) Immunoglobulin estimation
'  r —ru11"" i~ir —i— rr-m r—*r ii i n r iiii     i i i u i i i m iiim w im ia111# f im immi im
Serum and salivary immunoglobulin levels (IgG, IgA,
IgM) were measured by radial immunodiffusion and by the 
automated immunoprécipitation (A.I.P.) system.
i) Radial immunodiffusion
This technique utilises a precipitin reaction in
which/...
13-
which the internal reactant (specific antibody) is 
incorporated in a buffered agar medium. Serum 
containing the immunoglobulins (Antigen) is placed 
in a well centred in the immunodiffusion slide. By 
providing an unlimited amount of the antibody in 
the gel there will be no undue restriction on the 
diffusion of the antigen, resulting in a precipitin 
zone directly related to the amount of the antigen 
present. Reference sera were used with a knovm 
amount of antigens and their results plotted. The 
concentration of the unknov/n sera can be determined 
by reference to this graph (Fahey and McKelvey, 1963). 
Commercial radial immunodiffusion plates were 
purchased from ICL Scientific. Many of the immuno­
globulin assays were done by myself in this method, 
but they were repeated using nephelometry as explained 
below.
The Technicon A.I.P. system was used to measure 
serum and salivary immunoglobulins, utilising 
Technicon reference sera. The nephelometer measures 
the light scattered from the sample, which depends 
more on the number of molecules (Antigen - Antibody 
complexes) than on the size of the molecule. This 
may be important, when measuring the bigger size 
salivary IgA, bearing in mind that serum IgA standards 
were/...
14
were used as a reference for both serum and salivary 
IgA.
The method for the latter assay was carried 
out by the Department of Haematology, Southern 
General Hospital, Glasgow. I am grateful for this 
collaboration.
c) Serum and CSF folate *
A modification of the Lactobacillus Casei method 
(Herbert, 1966) was usëd, with a dilution of 1:20 for 
the serum, 1:100-1:200 for the CSF folate. The assay 
was carried out in the Haematology Department of the 
Southern General Hospital. I am grateful for this 
collaboration.
I
d) Homovanillic acid and 3-hydroxy-3-indole acetic 
acid in CSF
Samples of CSF were analysed with a spectrophoto- 
fluorimeter (Aminco Bowman 123, fitted with an off-axis 
ellipsoidal condensing mirror), by the method of 
Ashcroft, Crawford, Dow and Goldberg (1968). Each batch 
of samples was analysed together with a set of * standards* 
prepared in triplicate containing known quantities of 
HVA and HIAA in 5 ml of double distilled water. A ’blank* 
of 3 nil double distilled water was also used. This assay 
was carried out in collaboration with Dr. H. Keogh to 
whom I am grateful.
13.
SECTION I
As mentioned in the introduction, the control of 
seizures in epilepsy by use of anticonvulsants is still 
far from ideal, and some patients still have a large 
number of seizures in spite of being on multiple 
anticonvulsant drugs and these patients often present 
a social as well as a medical problem because of their 
poor seizure control and the deranged mental state ^hat 
often accompanies that.
Patients studied in this section fall into the 
category mentioned above and they are all chronic 
epileptics who are residential in an Epileptic Centre; 
despite multiple drug therapy and supervised intake of 
drugs, they still have a large number of seizures, 
which makes them unable to cope normally in the society*
It was felt that the group of patients mentioned 
above would be very suitable to study the effects of 
two recently introduced anticonvulsant agents, i.e. 
Sodium Valproate (EPILIM, Reckitt & Colman) and 
Clonazepam (RIVOTRIL, Roche Products), because of the 
poor seizure control and the effect that these drugs 
may have on other anticonvulsants. The effect of these 
two drugs and their side effects will be discussed in 
this section.
16.
CHAPTER 1
Comparison of sodium valproate (Epilim) and 
clonazepam (Rivotril) in intractable epilepsy.
INTRODUCTION
The introduction of new anticonvulsant drugs needs 
their assessment both individually and comparatively. 
Although two recently introduced drugs, clonazepam 
(Rivotril, Roche Products Ltd.) and sodium valproate 
(Epilim, Reckitt & Colman), have now been subjected to 
several different studies independently, comparative 
assessment of their value is still needed.
Clonazepam is a benzodiazepine closely related to 
other members of the group such as nitrazepam, diazepam 
and chlordiazepoxide (Fig, 1.1). It was shown to 
suppress generalised EEC abnormalities more readily than 
focal abnormalities (Gastaut, Courjon and Poire, 1971î 
Rossi, Di Rocco and Maira, 1973). It also enhances 
polysynaptic inhibitory processes at all levels of the 
central nervous system (Young, Zukin and Snyder, 1974).
Sodium valproate is structurally unrelated to any . 
of the known groups of anticonvulsant agents being a 
sodium salt of a fatty acid (Fig. 1.2) and its mode of 
action is postulated to be through interference with 
the GABA shunt of the tricarboxylic acid cycle (Fig. 1.3). 
The maximum seizure protection afforded by sodium 
valproate/...
Fig. 1,1 Structure of clonazepam (RIVOTRIL, Roche 
Products).
Pig, 1.2 Structure of sodium valproate (EPILIM, 
Reckitt & Colman).
CLONAZEPAM (Rivotril) Roche Products Ltd.
a BENZODIAZEPINE compound
SODIUM VALPROATE (EPILIM, Reckitt & Colman) 
Salt ol a fatty acid.
CH 2
CH
CH
 - COONa
Fig. 1,3 Tricarboxylic acid cycle (courtesy of 
Dr. P.K.P. Harvey, Department of Bio­
chemistry, Imperial College, London), 
showing the possible site of action of 
sodium valproate by inhibiting GABA 
transaminase and increasing GABA levels,
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valproate coincided with the maximum elevation of total 
brain GABA concentrations, but to produce this a very 
high dose of sodium valproate was needed, 400 mg/kg 
in mice (Simler, Ciesielski, Maitre, Randrianarisoa and 
Mandel, 1973).
One comparative trial between sodium valproate and 
clonazepam has been reported (Lance and Anthony, 1977), 
but it was carried out as an open trial, sodium valproate 
being given to patients in whom other drugs, including 
clonazepam, had not produced adequate control. The drugs 
were not therefore directly compared in the same patients. 
A cross-over trial was carried out in a group of patients 
who were poorly controlled on existing anticonvulsant 
therapy. Serum levels of sodium valproate and clonazepam 
as well as phenytoin, phenobarbitone and primidone were 
measured to try to see the correlation between the dose, 
serum level and seizure control, as well as the effect 
of the new drugs on the serum levels of other anticonvul­
sants, as will be reported in the next chapter.
FiLTHODS
Patients
Thirty-two adult chronic epileptic patients, all 
residents in the Epilepsy Centre, Quarrier's Homes,
Bridge of Weir, Renfrewshire, were studied. They were 
15 males and 17 females, aged 21-65 years (mean 56 years). 
All of the patients had epilepsy for ten or more years 
and/,,.
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and none had evidence of a progressive disease. They 
were all already on anticonvulsant medications 
phenytoin (20 patients), phenobarbitone (17), primidone 
(14), carbamazepine (10), ethotoin (2) and pheneturide 
(1).
The criteria of selection were that they had had 
more than five seizures per month for the preceding 
three months and in two separate estimations of anti­
convulsant drug concentrations in that period, the 
values were within the accepted therapeutic ranges for 
phenytoin (40-80 pmol/1) or phenobarbitone (40-160 pmol/
1).
Twenty-nine patients had frequent major seizures 
(generalised tonic-clonic fits), in addition to frequent 
minor seizures, absences, myoclonic attacks, focal attacks, 
including adversive attacks, Jacksonian attacks and 
temporal lobe attacks. These patients showed a variety 
of EEG abnormalities. Thirteen had bilateral slow wave 
or spike wave activities with no definite localisation; 
nine had temporal lobe foci; five had other focal lesions 
and two showed such low voltage activity that focal 
lesions could not be identified. The remaining three 
patients had minor seizures only and the EEGs showed 
respectively centrencephalic, temporal lobe and focal 
fronto-parietal abnormalities.
Trial Desi
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The trial consisted of three consecutive periods, 
each of twelve weeks. Patients who satisfied the 
criteria for selection given above were observed for 
twelve weeks during which serum concentrations of their 
anticonvulsants were estimated twice. The patients were 
then divided into two groups each of 16 patients. One 
was given sodium valproate (400 mg four times daily*, the 
dose being increased in four steps over a two-week 
introduction period), and the other was given clonazepam 
(2 mg three times daily, this value being achieved over 
two weeks in three steps). The trial drug was added to 
the patients* earlier regime. As far as possible, 
serum concentration of phenytoin or phenobarbitone was 
kept constant in all patients by I’educing their dosage 
if they showed an increase of more than 13%• After 12 
weeks on the first drug, each group crossed over to the 
other drug. The change was made over a six week period 
using a placebo matching the first trial drug. During 
the first two weeks of the cross-over period the first 
drug was replaced by placebo; in the second two weeks 
the patient continued on placebo only and in the third 
two weeks the second drug was built up and the patient 
then continued on the second drug for a further twelve 
weeks. There was therefore a period of two weeks during 
which the patients were on placebo only, to reduce the 
possibility/...
Fig. 1.4 Trial design; showing the cross-over 
fashion after 12 weeks on either drug.
The frequency of each observation is 
indicated by (.), as it was done in the 
study, (-) indicates one of the trial
drugs. (-- ) indicates that the patients
received placebo matching the drug used 
in the first 12 week period.
/
Drug
C lim cu l exam ination
Anticnn\’ulsants
EEG
Hiioniatoltigy and B iochem istry
Weeks 0 36 40 44
• * 
*
Fit frequency
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possibility of interactions between the two trial drugs.
Seizures were recorded by nursing staff as major 
and minor seizures as explained above. The reduction 
in seizure frequency is graded into 100% reduction,
75-100% reduction, 50-75% reduction, 50% reduction and 
worse (more seizures during drug treatment). The 
significances of difference were assessed by the Wilcoxon 
signed-ranks test.
Anticonvulsant analysis
Sodium valproate was measured by Gas Chromatography. 
Serum clonazepam levels were measured by radio-immunoassay 
(see under METHODS).
RESULTS
/
Seizure frequency
Of the 52 patients who started the trial, 15 patients 
completed all parts of the trial. The remaining 17 
patients completed one part of the drug trial only, 12 
completing the sodium valproate period and five completing 
the trial with clonazepam. Eight of these 17 patients 
left the trial after the first drug period for various 
reasons unrelated to the drug therapy. Another nine 
patients stopped taking the trial drug because of side 
effects; eight were on clonazepam and one on sodium 
valproate/...
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valproate.
When the average number of seizures per patient 
per month before and after treatment were compared in 
those 15 patients who completed the trial, a significant 
reduction in the frequency of minor seizures was found 
both with sodium valproate (P<0.005) and clonazepam 
treatment (P<0.02), Major seizures were also reduced 
with sodium valproate, but this failed to reach signifi­
cance (Fig. 1.5). Sodium valproate had the greater 
effect and reduced seizure frequency overall by more 
than 50%. The changes in seizure frequency, according 
to the type of epilepsy, are given in Tables 1.1 and 1.2.
Side effects
The main side effects with sodium valproate were 
drowsiness (25% of patients) and ataxia (17% of patients). 
These were abolished in all but one patient by reducing 
the serum concentration of phenobarbitone or primidone.
In one patient the drug was stopped because of these side 
effects. Gastro-intestinal symptoms (nausea, vomiting, 
diarrhoea) were noted in three patients during sodium 
valproate treatment, but it was mild and transitory. With 
clonazepam 65% of patients showed drowsiness and 55% of 
patients were ataxic. Because of side effects, the dose 
of clonazepam was reduced in 13 of the 29 treated patients 
from 6 mg to 1-5 mg/day and eventually stopped in eight 
patients.
Serum anticonvulsant concentrations/... •
Fig. 1.5 Histogram showing the average number of
seizures/patient/month in the 15 patients 
who completed the trial, during observation, 
sodium valproate, and clonazepam therapy. 
Differences were assessed by the Wilcoxon 
signed-ranlts test. (□) major seizures,
(0) minor seizures.
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Serum anticonvulsant concentrations
The serum concentrations of sodium valproate for 
all the patients treated with the drug, all receiving 
a dose of 1600 mg daily, ranged from 224-882 pmol/l 
(mean 497 t 184 SD pmol/l). The variation was generally 
fairly small, with 21 of the 26 (blood sample was not 
obtained from one patient) showing concentrations within 
the range of 350-700 pmol/l. There was no apparent 
relationship between the serum concentrations and the 
therapeutic effect: 18 patients v/ho showed a significant
( >50%) reduction in the total number of seizures had a 
mean concentration of 490 pmol/l and eight patients who 
showed little or no improvement had a mean concentration 
of 513 pmol/l.
i
The serum concentrations of clonazepam showed rather 
more variation. The mean serum concentration for 23 
patients in whom blood samples were obtained while 
they were receiving 6 mg of clonazepam daily was 82 ± 38 
SD nmol/1, but a number of patients showed lower serum 
concentrations throughout the major part of the trial 
since doses were later reduced. Twelve patients on doses 
ranging from 1 to 5 mg daily (mean 2.9 mg) showed a mean 
serum concentration of 29 t 19 SD. nmol/l. A possible 
correlation between serum concentrations and therapeutic 
effect was seen in the fact that (considering the 20 
patients who completed the clonazepam treatment period) 
the/...
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the four patients who showed a significant (> 50%) 
reduction in total seizures showed a serum clonazepam 
concentration greater than 50 nmol/l whereas eight of 
the 16 patients showing no improvement had levels below 
50 nmol/lc
In order to correlate the serum levels of clonazepam 
and sodium valproate to the patients* anticonvulsant 
medication dosage, a system of drug units was used* 
(Richens and Rowe, 1970). In this system, one unit 
represents each 50 mg of phenytoin or 30 mg of pheno­
barbitone, and 1.5 units represents 250 mg of primidone. 
Fig. 1.6 shows the relation of clonazepam concentrations 
to the drug units. There is a negative correlation 
between the two (patients who were on more drugs had 
lower serum clonazepam concentrations), while there was 
no correlation with sodium valproate (Figs. 1.6 and 1.7 
respectively).
The effects of both drugs on other anticonvulsant 
serum concentrations (phenytoin, phenobarbitone and 
primidone), as well as the effects these latter mentioned 
drugs have had on the trial drugs, will be discussed in 
the following chapter.
DISCUSSION
Both sodium valproate and clonazepam reduced the 
frequency of minor seizures when added to the existing 
therapy/...
Fig. 1.6 The correlation of serum clonazepam levels 
in nmol/l in 19 patients, all taking a dose 
of 6 mg/day, to the drug units (amount of 
other anticonvulsants the patients were 
taking). Negative correlation (P<0.01).
Fig. 1.7 Correlation between the serum sodium
valproate level in pmol/l in 21 patients, 
on a dose of 1600 mg/day, and the drug 
units (amount of other anticonvulsants the 
patients were taking). No significant 
correlation.
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therapy of patients whose fits had proved difficult to
control. Clonazepam was generally less effective than
sodium valproate although it appeared to be of value
in a few patients. Major seizures were also reduced
overall by sodium valproate, but this did not reach a
level of significance. Sodium valproate appeared to be
more effective in reducing seizures in patients with
generalised epilepsy than in those with focal epilepsy*
and this accords with findings in other centres 
(Jeavons and Clark, 1974; Meinardi, 1971).
Drowsiness was a major problem with clonazepam, 
and this required reducing the dose or stopping the 
drug in a considerable number of patients. Drowsiness 
also occurred in patients during sodium valproate treat­
ment, but appeared to be due to elevation of serum pheno- 
barbitone concentrations and was abolished by reducing 
the dose of phenobarbitone or primidone.
The effects of sodium valproate and clonazepam on 
phenobarbitone, primidone and phenytoin serum concentra­
tions will be discussed in the following chapter.
Variations in response to sodium valproate therapy 
between different patients did not appear to be related 
to variations in serum level of the drug. Most patients 
in the trial showed serum levels of sodium valproate in 
the range of 350-700 pmol/1 and other workers have found 
that/...
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that the therapeutic levels lie v/ithin this range 
(Barnes and Bower, 1975). By comparison, serum levels 
of clonazepam showed wide variation between different 
individuals. Administration of other anticonvulsants 
lowered the serum level of clonazepam and hence presumably 
the effectiveness of the drug. This corresponds with 
the previous findings of my colleagues who collaborated 
with me in this work (Nanda, Johnson, Keogh, Lambid and 
Melville, 1977), in,which they found that patients with 
high serum levels of phenobarbitone tended to have low 
serum concentrations of clonazepam; patients in that 
trial who were not receiving high doses of enzyme- 
inducing drugs such as phenobarbitone or primidone 
showed higher serum levels and better therapeutic control.
It appears that clonazepam is generally a less 
effective anticonvulsant drug than sodium valproate when 
added to standard anticonvulsant therapy, but it may be 
of value when used as a single drug or with low doses of 
other drugs; as it was found to be effective in the 
treatment of photosensitive and myoclonic epilepsy and 
in patients not receiving multiple drug anticonvulsant 
therapy, it was possible to increase the dose of 
clonazepam up to 12 mg daily without toxic effects.
There is therefore objective evidence for the 
greater value of sodium valproate when added to the drug 
therapy of patients already on anticonvulsants, compared 
with/,..
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with clonazepam. As it will be shown in the next 
chapter, this effectiveness of sodium valproate is 
independent from its effect on other anticonvulsants 
metabolism.
27*
SUMMARY
1. A cross-over comparative study of sodium valproate 
and clonazepam in the treatment of 32 adult chronic 
epileptic patients on multiple drug therapy is 
described. Fifteen patients completed all parts
of the trial; 12 patients completed only three 
months on sodium valproate and five patients completed 
only three months on clonazepam,
2, Both drugs significantly reduced minor seizures, 
more so with sodium valproate than with clonazepam 
treatment (P<0.005 and P < 0.02 respectively).
Major seizures were reduced with sodium valproate, 
but this reduction failed to reach significance.
3, Drowsiness and ataxia were the two main side effects 
and were much more marked with clonazepam requiring 
withdrawal of treatment in many patients.
4. Sodium valproate is a more useful anticonvulsant 
than clonazepam when given to patients on multiple 
drug therapy.
28.
CHAPTER 2
The effects of sodium valproate and clonazepam 
on the serum levels of phenytoin, phenobarbitone and 
primidone in patients on multiple anticonvulsant 
therapy.
INTRODUCTION *
The effectiveness, side effects and serum con­
centrations of sodium valproate and clonazepam were 
discussed in Chapter 1. However, another important 
question as regards their interactions with three 
commonly used anticonvulsant drugs, viz phenytoin, 
phenobarbitone and primidone, needs to be answered.
For example, serum phenobarbitone concentrations were 
reported to be increased by sodium valproate (Richens 
and Ahmed, 1975). It is also important to see whether 
or not the effects of control seen with each of the 
trial drugs is secondary to elevation of the serum levels 
of another drug.
METHODS
Thirty-two adult chronic epileptic patients who 
were reported upon in Chapter 1 were studied and their 
serum phenytoin, phenobarbitone and primidone levels 
were monitored at four-weekly intervals to try to keep 
the/...
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the serum concentrations of phenytoin, phenobarbitone 
and primidone within 15% of the base line in either 
direction.
Serum phenytoin, phenobarbitone and primidone were 
measured by Gas Chromatography (see under METHODS).
The differences in serum concentrations of anti­
convulsants were compared using the Wilcoxon signe^- 
ranks test.
RESULTS
Seven patients showed an increase greater than 
15% in serum phenobarbitone concentration when sodium 
valproate was added to their treatment. Five were 
receiving phenobarbitone and two were receiving 
primidone. Six of these patients showed side effects 
of drowsiness and ataxia. In all these patients, the 
dose of phenobarbitone or primidone was reduced. One 
of these patients also showed an increase in serum 
phenytoin concentration and in this case the phenytoin 
dose was reduced.
The phenobarbitone serum concentrations in the 
patients receiving phenobarbitone itself were signifi­
cantly raised (P<0.05, Wilcoxon signed-ranks test), 
with the mean increasing from 142 ± 25 SD ^mol/1 to 
184 ± 75 SD pmol/1 on administration of sodium valproate; 
the/...
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the serum concentrations of phenobarbitone in patients 
receiving primidone were generally unchanged. There 
was a significant fall (P<0.05) in serum phenytoin 
concentrations with sodium valproate therapy (Fig. 2.1).
No significant effects on serum levels of phenytoin, 
phenobarbitone or primidone were observed with clonazepam 
therapy,
»
.DISCUSSION
Overall, sodium valproate administration to 
patients on other anticonvulsants produced a significant 
increase in mean serum phenobarbitone concentration in 
patients receiving phenobarbitone, but not in patients 
receiving primidone. The mechanism of the effect of 
sodium valproate on serum levels of phenobarbitone is 
unknown, but the most likely hypothesis is that the 
drug inhibits metabolism of phenobarbitone. The apparent 
lack of effect of sodium valproate on phenobarbitone 
levels in patients receiving primidone might be explained 
by an inhibition by sodium valproate of primidone 
metabolism to phenobarbitone. Since the phenobarbitone 
or primidone dose was decreased in patients in whom 
serum levels of phenobarbitone significantly increased, 
it is likely that most of the therapeutic benefit 
obtained in patients during sodium valproate therapy was 
due/...
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due to the action of the drug itself. However, 
evaluation of the drug in individual patients should 
take the possibility of drug interactions into account. 
For example, Fig. 2.2 shows serum drug concentrations 
and seizure control for a patient in whom the pheno­
barbitone serum level showed a dramatic increase on 
sodium valproate administration; the period before the 
phenobarbitone dose was decreased showed the lowest^ . 
seizure frequency. However, the period after that the 
patient*s seizure frequency was still less than the 
observation period and the drowsiness which appeared 
after the introduction of sodium valproate disappeared 
after reduction of phenobarbitone dose.
A significant decrease in serum levels of phenytoin 
was found on sodium valproate administration. This 
effect has been observed by other workers and it may be 
due to a displacement of phenytoin from its plasma 
protein binding sites (Patsalos and Lascalles, 1977). 
However, one patient showed a large increase in the 
phenytoin serum level which required dose reduction; 
this patient showed a concurrent increase in the pheno­
barbitone serum level and it is likely that this may have 
caused inhibition of phenytoin metabolism (Lambie, 
Johnson, Nanda and Shakir, 1976). A displacement of 
phenytoin from 'its protein binding sites may increase 
brain concentrations (Patsalos and Lascalles, 1977); 
further/...
Fig. 2.1 Serum levels of phenytoin, phenobarbitone 
and primidone in pmol/l before and during 
treatment with sodium valproate. Showing 
a significant increase in phenobarbitone 
(P<0.05) and a significant decrease in 
phenytoin (P<0.05) (using Wilcoxon signed- 
ranks test).
Fig. 2.2 Serum levels of phenobarbitone (#), phenytoin
(O), and frequency of major (O) and minor 
(C3) seizures in one patient before and after 
addition of sodium valproate to the treatment. 
The phenobarbitone level increased, but when 
the dose was reduced the improvement in 
seizure frequency remained.
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further study of this as a possible factor involved in 
the therapeutic effect of sodium valproate would be 
desirable.
Variations in response to sodium valproate therapy 
between different patients did not appear to be related 
to variations in serum levels of the drug.
33.
SUMI'ÎARY
When sodium valproate or clonazepam were added 
to the anticonvulsant regimes of 32 adult chronic 
uncontrolled epileptic patients in a cross-over pattern
(1) serum concentrations of phenytoin, phenobarbitone 
and primidone were unchanged when clonazepam was 
added;
(2) with sodium valproate, serum phenobarbitone 
concentrations increased (P<0.05) in patients 
on phenobarbitone, but not significantly in 
patients on primidone;
(3) phenytoin concentrations were reduced (P<0.05) 
during treatment with sodium valproate.
34,
SECTION II
This section deals with some of the effects 
that anticonvulsants have on the metabolism. The 
two effects that I s'budied were those on immuno­
globulin and folate metabolism.
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CHAPTER 3 
Serum IgA depletion in epilepsy
INTRODUCTION
Various immunological abnormalities have been 
reported during anticonvulsant therapy, including 
depression of both humeral and cellular immunity, in 
particular low serum immunoglobulin A (IgA) (Sorrell, 
Forbes, Burness and Rischbieth, 1971; Grob and Herold,
1972). Serum IgA depletion was not thought to be 
related to phenytoin therapy and was associated with 
higher incidence of psychiatric symptoms (Slavin, Fenton, 
Laundy and Reynolds, 1974). It was suggested that the 
IgA depletion was present in epileptic patients before 
the commencement of phenytoin therapy which accentuates 
it, and the deranged immunological finding may have some 
role in the aetiology of epilepsy (Seager, Jamison,
Wilson, Hayward and Soothill, 1975).
1 METHODS
Eighty-three epileptic patients were studied (40 
females and 43 males) whose ages ranged between 17 and 
76 years with.a mean of 41 years. The patients were 
divided into two groups: Group A consisted of 56 patients,
24/...
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24 female and 52 male, who were taking phenytoin in 
addition to other anticonvulsants; and Group B 
consisted of 27 patients, 15 female and 12 male, who 
were on anticonvulsants other than phenytoin. The 
duration of treatment was more than 10 years in all 
patients; the drug regimes of all the patients are 
shown in Table 3,1. Seven patients in Group A and 
four in Group B had family history of epilepsy. There 
was no patient included who suffered from neoplasia 
or any of the presumed ,auto-immune diseases.
Serum immunoglobulins; IgG, IgA and IgM were 
measured simultaneously by radial immunodiffusion 
(R.I.D, ) and by the Technicon A.I,P. system*
Serum, anticonvulsants: serum phenytoin, pheno­
barbitone and primidone were measured by gas chroma­
tography.
Serum folates: measured by the Lacto-bacillus
Casei method (for all assay techniques, see under METHODS).
■ RESULTS
The 100% mean normal adult value (M.N.A.) was as 
follows;- IgG- 947 mg/dl, IgA - 248 mg/dl, IgM - 94 rag/ 
dl, and the normal range for each was 50-175% M.N.A.
(Fahey and McKelvey, I965).
In/...
DRUGS Group 1 (56) Group 2 (27)
Phenytoin 56 -,
Phenobarbitone 29 11
Primidone 18 16
Carbamazepine 8 8
Sodium valproate 9 5
Clonazepam 1 1
Ethotoin - 2
able 3.1 : Group A - 56 patients all on phenytoin
Group B “ 27 patients 
convulsants
on other anti-
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In both groups, normal levels of IgG and IgM 
were found. With regard to IgA, "however, a conspicuous 
difference was seen between Groups A and B (Fig. 3.1).
In Group A, 13 patients (23.2%) had a low serum IgA 
concentration; less than 50% M.N.A., while in Group B 
only one patient had a slightly reduced IgA level 
(46% M.N.A.). The findings were consistent and when 
they were repeated after a month in 21 of the patients, 
while maintaining the same anticonvulsant dosage, the 
results showed a very good correlation (Pig. 3.2)
(r = 0.962; P< 0.001). The two methods used for the 
assay of the immunoglobulins, i.e. R.I.D. and nephelo- 
metry, again showed consistent results (r = 0.894;
P < 0.001) (Fig. 3.3).
Serum anticonvulsants
No correlation was found between the dose or the 
serum concentration of phenytoin and the degree of IgA 
depletion. In Group A, however, patients who had low 
serum IgA levels had lower serum primidone levels than 
patients with normal serum IgA, while the serum pheno­
barbitone derived from primidone was not different in 
the two groups. Four of the patients with low IgA were 
on phenobarbitone and these had a high serum level when 
compared with those with normal serum IgA in Group A 
and patients in Group B in spite of the fact that they 
were on comparable doses (Table 3.2). The primidone and 
the/...
Fig, 3,1 Serum IgA mg/dl in 56 patients on phenytoin, 
and 27 patients on anticonvulsants other 
than phenytoin. Thirteen patients in the 
first group had levels below 50% Mean Normal 
Adult (M.N.A.). Only one patient in the 
second group had a slightly reduced level.
/
Patients on 
Phenytoin
Patients on 
other drugs
Serum  Ig A mg/dl.
700
600
500
400
300 50-175% M.N.A.
20C
100
n - 56 n - 27
Pig, 3,2 Serum IgA in mg/dl in 21 patients on phenytoin.
Correlation of levels done on two occasions, 
r = 0.962, P <0.001.
Fig. 3*3 Serum IgA in mg/dl. Correlation between radial 
immunodiffusion and nephelometry in 21 patients 
on phenytoin. r = 0.894, P <0.001.
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the phenobarbitone levels were significantly different 
(P< 0.05 for both using Student’s t test) in the two 
groups of patients, but because of the small number of 
patients, this finding is not considered to be important.
Serum folate levels
Low serum folate levels were found in both Groups 
A and B (2.22 pg/1 ± 0.95 SD and 3.164 pg/l ± 1.56% SD, 
respectively). The normal range of serum folate by the 
method used is 7 - 15.9. pg/1 and the lowest limit of 
the intermediate range is 3 pg/l (Herbert, 1966). There 
was a significant difference between Groups A and B, 
patients in Group A having lower serum folate levels 
(P<0.0005 using Student’s t test). There was no 
correlation between the serum folate levels and the IgA 
deficiency. Patients with low serum IgA had a mean 
serum folate of 2.55 pg/1 1 1.003 SD.
There was no correlation between the type of epilepsy, 
seizure control or the incidence of psychiatric symptoms 
and the serum IgA levels. Only three patients of the 
13 with low serum IgA had a positive family history of 
epilepsy.
• DISCUSSION
IgA deficiency is the most commonly reported 
immunologic defect in man. One in 300 to 800 persons 
have/o.o
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have selective IgA deficiency (Koistinen, 1973). Not 
all of these people manifest disease. Therefore additional 
factors appear to contribute to the ultimate expression 
of disease.
There is good evidence that immunological abnormal­
ities are found in patients taking anticonvulsants.
Several workers have found low serum IgA levels and
*
evidence of impaired T-cell function (Sorrell and Forbes,
1973). The mechanisms involved in producing the immune 
changes are unknown.
Nearly one-fourth of the patients (23.2%) who were 
on phenytoin had low serum IgA levels, while only one 
patient from Group B had even a slightly reduced level, 
and it is interesting to note that this patient was on 
carbamazepine, which was reported to cause IgA depletion 
in 11% of patients (Sorrell and Forbes, 1975). In the 
patients affected, there was no relationship between 
phenytoin dosage or serum level and the degree of IgA 
depression. The reduced serum primidone levels which 
were found in pati ents with low serum IgA have been 
reported previously (Slavin et al., 1974), but the 
explanation of this is unknown,
IgA function is related to intact thymic function 
(Lancet, 1975). It is known that congenitally athymic 
nude mice have IgA deficiency although they have many 
IgA/...
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IgA bearing B lymphocytes (Bankhurst and Warner, 1972). 
This is similar to patients with IgA deficiency secondary 
to phenytoin therapy (Sorrell and Forbes, 1975), who 
also have normal numbers of IgA bearing B lymphocytes, 
but low serum IgA levels. In animal experiments impaired 
immune responses, atrophy of thymic and lymphoid tissue 
and increased incidence of lymphoid tumours were produced 
by chronic phenytoin ingestion (Kruger and Harris,*1972), 
and indeed increased incidence of malignant lymphomas 
associated with phenytoin therapy in epileptic patients 
has been reported (Anthony, 1970).
The mechanism of production of low serum IgA by 
phenytoin is not yet understood. A direct action of the 
phenytoin on the plasma cell situated in the submucous 
layers mainly of the gut and the respiratory system is 
possible, but there must be another factor which pre­
disposes some patients to develop the deficiency as long 
as it is not dose or serum level related. This factor 
was suggested to be a constitutional one, and this will 
be investigated in Chapter 5. Another factor which might 
be operative is the folate deficiency which may limit 
protein synthesis (Norris and Pratt, 1974). The incidence 
and the effects of folate deficiency will be discussed in 
later chapters of this thesis.
Reduced serum IgA has been found in patients with a 
variety of auto-immune disorders, including systemic lupus 
erythematosis/..•
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erythematosis (Tomasi, 1968), pernicious anaemia 
(Odgers and Wagel, I968), Sjogren's syndrome (Claraan, 
Hartley and Merrill, 1966; Hobbs, I968), and myasthenia 
gravis (Simpson, Behan and Dick, 1976), and in a variety 
of malignancies (Scheurlen, Schneider and Pappas, 1971).
In the patients with low serum IgA level, the 
incidence of psychiatric symptoms was not more than in 
those with normal levels and all of them were on pheny­
toin, a finding which does not support the results of 
Slavin et al. (1974) who have suggested that the IgA 
deficiency is not related to anticonvulsant therapy and 
especially phenytoin, and who have reported an increased 
incidence of psychiatric symptoms in the low IgA group 
of their patients. The abnormality of reduced serum 
IgA during phenytoin therapy was reported to be of a 
greater extent in female patients, with depression of 
IgM levels (Sorrell and Forbes, 1975). However, the 
findings in this study were that the 13 patients with low 
IgA showed a male;female ratio of 9:4, and the serum IgG 
and IgM were not different in the low IgA group from 
other, patients and indeed they were within the normal 
limit, which is not in agreement with other workers 
(Slavin et al., 1974).
Patients with low serum IgA did not have an increased 
liability to infection as would be expected in some of 
them (South, Cooper, Wollheim and Good, 1968). This 
really/...
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really depends on the state of the secretory IgA in their 
mucosal secretions; although this has been reported to 
be reduced (Aarli and Tonder, 1975), absence of increased 
liability of sino-pulmonary or other infections does not 
seem to support this. In addition, the low salivary IgA 
was postulated to be a contributing factor in the 
development of gingival hyperplasia which is a common 
complication of phenytoin therapy. However, other * 
workers (Harris and Rowe, 1976), in examining 103 epi­
leptic patients, showed, a 659^  incidence of gingival 
hyperplasia and its degree was correlated with high serum 
concentrations of alkaline phosphatase. In view of these 
reports, salivary IgA was studied, details of which are 
in the following chapter.
43.
SUmARY
1. Serum IgA was found to be reduced in 23.2% of 
56 patients taking phenytoin as part of their 
anticonvulsant medication and only slightly reduced 
in one of 2? patients on anticonvulsants other 
than phenytoin.
2. The IgA deficiency was not related to the dose 
or the serum concentration of phenytoin.
3. No difference in the serum IgG or IgM was noted
!
between the two groups.
4. Serum folate was low in both groups, but the 
reduction was more in the group that was on 
phenytoin and the difference was statistically 
significant.
5. There was no correlation between the serum IgA 
level and the seizure control or duration of the 
disease, and there was no specific liability to 
infection in the group who had low serum IgA levels.
44.
CHAPTER 4
Salivary IgA in patients on phenytoin
INTRODUCTION
The plasma cells present in the submucous layer 
of the respiratory, gastro-intestinal and urinary tracts 
produce IgA which has the function of acting as an 
antibody on these mucosal surfaces (Pig.4.1). The IgA 
molecule passes through the epithelial lining of the 
mucosa and during its passage two IgA molecules are 
attached together with another substance called the 
secretory piece; the product is called secretory IgA 
which is resistant to the action of protealytic 
enzymes (Tomasi, 1971). The production of secretory 
IgA into external secretion is controlled independently 
of systemic immunological reactions and the distribution 
of secretory IgA differs strikingly from that of the 
serum (Walker and Isselbacher, 1977).
"One way of looking at the secretory IgA is by 
measuring its concentrations in saliva. In a recent 
study in epileptic patients who were on phenytoin,with 
low serum IgA concentrations, the secretory IgA was shown 
to be reduced in whole saliva and this was correlated 
with gum hyperplasia (Aarli and Tender, 1975).
In Chapter 3 of this thesis, the patients who were 
found/...
Fig, 4,1 Synthesis and transport of secretory IgA,
(Tomasi, 1971). Plasma cell in the submucous 
layer secretes IgA which goes through the 
mucosal layer, where two molecules are attached 
together by the secretory piece.
/
Synthesis and Transport of Secretory Ig A
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found to have low serum IgA concentrations did not show 
an increased incidence of sinopulmonary infections, and 
gingival hyperplasia was not confined to them. Gingival 
hyperplasia has been correlated with high serum concentra­
tions of bone alkaline phosphatase (Harris and Rowe, 1976)* 
In addition, the patients with low serum IgA did not show 
an increased liability to infections as would be expected 
in patients with reduced IgA on their epithelial surfaces 
(Tomasi, 1971).
PATIENTS and METHODS
Seven epileptic patients with low serum IgA 
concentrations, six other epileptic patients with normal 
serum IgA, and 10 healthy control adults were studied.
The two groups of epileptic patients were taking pheny­
toin in addition to other anticonvulsants (Table 4,1).
In both groups of patients, the serum IgA concen­
trations were measured on three occasions, except in 
three patients where it was done twice.
Saliva was collected from one or the othei parotid 
duct opening using Carlson-Crittenden cups. Both salivary 
and serum IgA were measured by the A.I.P, system.
Serum anticonvulsants - phenytoin, phenobarbitone 
and primidone - were measured by Gas Chromatography (for 
details of the techniques see METHODS),
RESULTS/,,,
DRUGS LowSerum IgA
Normal 
Serum IgA
Phenytoin 7 6
Phenobarbitone 3 4
Primidone 3 2
Carbamazepine 2 1
Sodium Valproate - 1
Table 4.1 : Drug therapy in the patients examined
/
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RESULTS
Tables 4.2 and 4.3 show the serum IgA concentra­
tions in mg/dl with their means,and the % Mean Normal 
Adult value of the means, and it is very evident that 
in the two groups there is a big difference between the 
serum IgA concentrations. The salivary IgA concentra­
tion results are shown in Table 4.4 in both groups of 
patients and in the controls. Trying to look at the 
secretory IgA as part of the IgA system, the salivary 
value is expressed as a percentage of the serum level, 
although in absolute terms the salivary IgA concentration 
was lowest in the patients with low serum IgA concentra­
tions (statistically not significant), but the percentage 
of salivary to serum concentrations was the highest, 
a mean of 40.7% compared to the controls mean of 10.9%
(P< 0.01 using Student's t test).
Serum anticonvulsant concentrations for both groups 
of patients are shown in Table 4.5, and it is evident 
that both groups of patients were under adequate dosage 
of anticonvulsants. The serum IgA depletion was not 
related to the serum phenytoin level,as the low IgA 
group had a lower mean serum phenytoin concentration.
DISCUSSION
The presence of reduced serum IgA concentration does 
not/,,.
Patients with low serum IgA
Patients
Serum IgA mg/dl
Mean
»
% M.N.A.
First Second Third
1 70 60 100 76 30.6
2 115 110 90 105 42,3
3 0 20 10 4
4 20 0 45 21,6 8.7
5 90 95 92,5 37.2
6 35 — 30 32.5 13.1
7 30 20 5 18.3 7.3
Table 4.2 : Serum IgA levels on three occasions in 
four patients and two occasions in 
three patients, in mg/dl, with the mean 
and the mean normal adult percentage 
(M.N.A.%)
Patients with normal serum IgA •
Patients
Serum IgA mg/dl
Mean
*
% M.N.A.
First Second. Third
1 475 360 430 421 169
2 390 330 380 366 147
3 340 310 210 286 115
4 370 340 310 340 137
5 270 240 180 230 92
6 405 380 270 351 141
Table 4.3 : Serum IgA levels on three occasions in 
mg/dl with the mean and the mean normal 
adult percentage (M.N.A.%)
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not necessarily indicate a similar reduction of 
secretory IgA. Indeed, there is little consistent 
relationship between secretory and serum IgA levels, 
and there are several infants reported with significant 
amounts of secretory IgA, but no detectable serum IgA 
(Tomasi, 1971). The other fact that stimulated this 
work was that the patients with low serum IgA did not 
show an increased incidence of infection, particularly 
of the respiratory tract.
Salivary IgA was r'eported to be reduced in patients 
on phenytoin and was correlated with gum hypertrophy 
(Aarli and Tonder, 1975). On the other hand, gum 
hyperplasia was correlated with high serum alkaline 
phosphatase in 65% of 103 patients (Harris and Rowe, 
1976). In the patients studied here the degree of gum 
hypertrophy was not different or more pronounced in the 
patients who had low serum IgA.
An important finding as regards the level of 
salivary IgA in controls is noted. Previous reports 
on parotid saliva IgA concentrations in unstimulated 
healthy adults have shown a mean of 4.5 mg/dl (Oon and 
Lee, 1972), while in mixed saliva the mean secretory 
IgA was reported as between 3.2 and 4,5% of the serum 
levels in 10 healthy adults (Aarli and Tonder, 1975).
In both studies, radial immunodiffusion, using low 
concentration Agar plates, was the method by which 
salivary/...
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salivary IgA levels were measured. In this study, 
parotid saliva was collected unstimulated to avoid the 
dilution effect which had been reported previously 
(Oon and Lee, 1972), and nephelometry was used to 
measure the concentration of the immunoglobulins. This 
may have led to the higher salivary IgA concentrations 
because the number of molecules and not the speed of 
diffusion of the larger secretory IIS particles was. 
measured. In both studies mentioned above and indeed 
in this one, serum IgA was used as a standard. Another 
point worth mentioning here is the great fluctuation 
in parotid salivary IgA concentration when measured at 
weekly intervals by electroimmunodiffusion and the 
values in the controls in this study certainly fall 
within the range of normal fluctuation (Claman, Merrill 
and Hartley, I967). ' Another finding stated by the 
last mentioned authors was the lower secretory IgA 
found in submandibular-sublingual saliva than in parotid 
saliva, which would explain a lower IgA in whole saliva 
when compared to parotid secretory IgA.
The finding of a higher percentage of salivary IgA 
when compared to the serum level in this study would 
point to a possibility that there is some effect on the 
serum IgA, possibly excessive destruction, or more likely 
perhaps that there is a direct effect on the plasma cell. 
This may have led to partial, but not complete, impair­
ment of function, and whatever IgA produced is prefer­
entially/...
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entially thrown out through the mucosal layer to become 
the secretory IgA,which is after all the functional IgA 
in the body. This may therefore lead to a reduction in 
the serum IgA level. The local plasma cell is the 
important factor in the function of the secretory IgA.
This important local effect has been demonstrated in 
another way, by introducing inactivated polio virus 
into double-barreled colostomies, the highest IgA * 
antiviral antibody levels were obtained from sites in 
direct contact with the virus. This was not seen in 
sites distant from the site of introduction (Tomasi,
1976).
There was no relation between the salivary IgA 
concentration and the dose or serum level of phenytoin, 
and this is in accordance with the findings in Chapter 
3 of this thesis.
In conclusion, the secretory IgA seems to be affected 
to a much lesser degree than the serum IgA in epileptic 
patients who are on long-term anticonvulsant medication, 
indicating perhaps a partial or incomplete inhibitory 
effect on the plasma cell present in the submucous layers 
of the gastro-intestinal and respiratory tracts,
IgA deficiency will be studied further in the next 
chapter as regards correlation with the HLA system and 
possible constitutional predisposition to IgA deficiency 
in patients who take phenytoin.
50.
SUMMARY
1. Secretory IgA was not found to be depressed to 
the same degree as serum IgA in patients on 
long-term phenytoin therapy.
*
2. Gum hypertrophy, a common side effect of chronic 
phenytoin intake,was not related to reduced 
salivary IgA.
3. The method by which phenytoin affects serum 
IgA level might be through partial inhibition 
of the plasma cell in the submucous layers of 
epithelial covers of the gastro-intestinal and 
respiratory tracts.
4. Unstimulated parotid saliva may be a better way 
of studying secretory IgA than mixed saliva.
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CHAPTER 5
Metabolism of immunoglobulin A, lymphocyte 
function and histocompatibility antigens in patients 
on anticonvulsants,
INTRODUCTION
As discussed in the previous two chapters, serum *
IgA levels were found to be depressed in roughly 25% 
of patients who are on long-term phenytoin therapy. 
Cell-mediated immunity has been measured in vivo by 
skin testing with ubiquitous recall antigens, and in 
vitro by measurement of lymphocyte DNA and RNA 
synthesis. It was found to be depressed; low serum 
IgA levels together with defective antibody production 
to Salmonella tvphii and tetanus toxoid were also found 
(Sorrell and Forbes, 1975). It was subsequently 
suggested that epilepsy with constitutional character­
istics might predispose to low IgA and that the low IgA 
only occurs when phenytoin is given (Fontana et al., 1976).
PATIENTS and METHODS
From the 83 patients that were studied in Chapter 
3 of this thesis, 30 patients were selected for this 
study. Ten patients were taking phenytoin as part of 
their/...
52.
their anticonvulsant medication and were shown to have 
consistently low serum IgA levels (below 50% M.N.A.),
Ten other patients were having phenytoin as well, but 
had consistently normal serum IgA levels. The last 
group of patients were 10 patients who were on anti­
convulsant drugs other than phenytoin (including pheno­
barbitone, primidone, carbamazepine, and sodium valproate) 
and had normal serum IgA levels.
Peripheral blood lymphocyte protein synthesis
The synthesis of protein by peripheral blood 
lymphocytes was measured by the whole blood technique 
(Behan, Behan, Zacharias and Nicholls, 1976). This 
method estimates the uptake of tritiated leucine by 
peripheral blood lymphocytes on stimulation with purified 
phyto-haemagglutinin (PHA) over a period of 22 hours. 
Lymphocytes from the 30 patients described above were 
studied. A dose response curve to various concentrations 
of purified PHA (Burroughs Wellcome) was drawn from each 
patient. Protein synthesis by lymphocytes was also 
measured in 35 healthy control adults.
HLA typing;
Twenty of the 30 patients mentioned earlier were 
typed for their histocompatibility antigens (HLA).
These were the patients who were taking phenytoin, half 
of them had low serum IgA and the other half had normal 
serum/...
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serum IgA levels. HLA typing was carried out by a 
modification (Dick, Crichton, Ferguson-Smith and Izatt, 
1972) of the lymphocytotoxicity testing using glass 
plates, described by Kissmyer-Nielsen and Kjerbye (1967).
RESULTS
HLA typing
The HLA pattern is shown in Table 5.1. There 
were eight patients with HLA-A2 in those with low serum 
IgA compared to three in those with normal serum IgA,
Optimum stimulation was obtained at a PHA concen­
tration of 8.33 pg/ml. Responses to PHA are expressed 
as the ratio of the counts/minute with PHA to counts/ 
minute in the unstimulated cultures. A highly significant 
depression of protein synthesis was found in all 30 
patients when compared to the controls (Fig 5.1).
DISCUSSION
There is good evidence that immunological abnormal­
ities are found in patients taking anticonvulsants. It 
was demonstrated in the previous two chapters that 
phenytoin affects the IgA producing plasma cells and 
indeed other workers have shown evidence of impaired 
T-cell/...
Fig, 5ol Lymphocyte protein synthesis in response to 
phyto-haemaglutinin (PHA) at a concentration 
of 8.33 pg/ml.
A : Patients with low IgA on phenytoin and other 
drugs (P<0,0001).
B ; Patients with normal IgA on phenytoin and 
other drugs (P<0.0001),
C : Patients with normal IgA on other drugs 
(P< 0.0001).
D ; Normal controls (35).
Differences were assessed using Student's t 
test.
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1 50 -
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Patients HLA-A HLA.
1
-B
Low serum IgA group
male 2 3 7 ¥17
female 2 28 8 14
male 2 3 27 ¥16
male 2 ¥19 14 ¥21
female .2 . 7 13
male 2 3 5 ¥15
male 2 9 7 ¥16
male 2 9 5 7
female 3 ¥26 27 ¥40
male 3 9 7 12
Normal serum IgA group
male 2 3 7 ¥14
female 2 11 12 ¥37
male 2 ¥25 ¥40
female 1 9 7 8
female 1 2 8 ¥15
female 1 8 ¥17
male 1 29 ¥17
male 3 ¥52 7 ¥35
female 3 ¥32 8 ¥27
male 3 7
Table 5.1 •: HLA typing in 20 patients on
phenytoin.
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T-cell function as measured both in vivo by lack of 
cutanous reactivity to ubiquitous recall antigens, and 
in vitro by impaired lymphocyte DNA and RNA synthesis 
(Sorrell and Forbes, 1975). The mechanisms involved 
in producing these immune deficiencies are unknown, 
but it has been suggested that a genetic factor may be 
operative (Fontana et al., 1976).
A
The results of this work show a conspicuous 
impairment of T-cell function. The technique used to 
measure T-cell function was the inyitrq measurement 
of peripheral blood-lymphocyte protein synthesis. This 
technique has been demonstrated to be a sensitive and 
reliable index of thymus-derived lymphocyte function 
(Pauly, Sokal and Han, 1973). Impaired immune responses 
by this method have previously been demonstrated in 
patients with auto-immune diseases, drug reactions and 
malignancies (Thomas, Lannigan and Behan, 1975; Behan 
et al.. 1976; Simpson, Behan and Dick, 1976).
It is possible that phenytoin causes depressed T- 
cell function by direct action on cells. This hypo­
thesis is supported by evidence of the action of pheny­
toin on normal lymphocytes in culture, where it produces 
depression of both DNA and RNA synthesis (Sorrell and 
Forbes, 1975).- However, in this study, patients who 
were taking anticonvulsants other than phenytoin had a 
similar depressed lymphocytic response. A factor common 
to/,,.
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to both groups and demonstrated in Chapter 3 of this 
thesis was reduced serum folate levels; this is known 
to affect cellular nucleic acid synthesis (Norris and 
Pratt, 1974). This effect of anticonvulsants on folic 
acid metabolism will be the subject of study in the 
following chapter of this thesis.
The most interesting association was the increased 
frequency of the histocompatibility antigen HLA-Ag in 
the patients taking'phenytoin with low serum IgA levels. 
Although the sample size was small, the difference 
between the two groups was striking and strongly supports 
the hypothesis that phenytoin causes selective IgA 
depletion in genetically predisposed individuals.
56.
SUÎ-IMARY
1* Impaired T-cell function demonstrated by depressed 
protein synthesis of peripheral blood lymphocytes 
upon stimulation with PHA has been shown to be, 
present in 30 epileptic patients on chronic anti­
convulsant medication,
2, The impaired T-cell function was not related to 
any specific anticonvulsant,nor to patients who 
had reduced serum IgA as a result of phenytoin 
intake.
Ï
3, The effect on T-cell function could be due to a 
common factor perhaps folate deficiency secondary 
to anticonvulsant medication,
4, The patients with reduced serum IgA had a higher 
incidence of the histocompatibility antigen HLA-A2 
which was significantly higher than those patients 
who were on the same medication but had a normal 
serum IgA, suggesting a genetic predisposition to 
develop selective IgA deficiency after intake of 
phenytoin.
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CHAPTER 6
Serum and cerebrospinal fluid folate levels in 
epilepsy.
INTRODUCTION
Reduced serum folate levels have previously been 
reported in a large percentage of patients taking anti­
convulsant medication. This varied from 33™99% (Hawkins 
and Meynell, 1958; Klipstein, 1964; Malpas, Spray and 
Witts, 1966; Jensen and Olesen, 1970; Norris and 
Pratt, 1971; Reynolds, Mattson and Gallagher, 1972).
In Chapter 3 of this thesis, low serum folate levels 
were noted in the patients examined. This was more pro­
nounced in those who.had phenytoin as part of their 
anticonvulsant medication. The cerebrospinal fluid 
folate concentration is normally higher than that of the 
serum (Wells and Casey, I967), but CSF folate was also 
reported to be reduced in epileptic patients on anti­
convulsants (Reynolds et al., 1972). In the following 
chapter of this thesis, the extent of folate deficiency, 
and the effects of treatment of folate deficient 
epileptics will be studied, and the patients in this 
chapter who had the lowest serum folate levels will be 
the subject of further study in the next chapter.
METHODS
Fifty-two adult epileptic patients, age range 17-
63/...
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63, mean 38 years, were studied. They were 27 females 
and 25 males. All were on multiple anticonvulsant drug 
therapy: phenytoin 35 patients, phenoharbitone 25
patients, primidone 25 patients, in addition to carba- 
mazepine, sodium valproate, clonazepam and ethotoin.
Serum folate measurements were done in all the 
patients. CSF folate was subsequently measured in 20
k
patients who had the lowest serum folate levels and in 
those 20 the serum folate was measured twice. CSF was 
obtained by lumbar puncture within one hour of awakening 
in the morning; blood was taken simultaneously for 
serum folate estimation. Serum and CSF folate were 
measured by the Lactobacillus Casei method (see under 
METHODS), Serum phenytoin, phenoharbitone and primidone 
were measured by Gas,Chromatography, For correlating 
serum and CSF folate concentration, data were logarithm­
ically transformed because the folates are log normally 
distributed (Reynolds, Gallagher, Mattson, Bowers and 
Jotmson, 1972).
RESULTS
Serum folate levels in all the patients had a mean 
of 2 pg/l ± 0.91 S.D. Five patients only had a serum 
level above 3 )4s/l (90.3% had low serum folate). Of the 
20 patients in whom lumbar punctures were performed to 
obtain CSF, only 17 patients had their CSF samples 
successfully/...
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successfully obtained; the serum folate level in them 
was 1.74 pg/1 ± 0.48 S.D., and the CSF folate levels 
had a mean of 8.35 pg/1 - 3.86 S.D., a ratio of serum : 
CSF of 1 : 4.8, but there was no significant correlation 
between the serum and the CSF folate levels in the group 
examined (Fig. 6.1).
Serum anticonvulsant concentrations: serum
*
phenytoin levels had a mean of 66.45 pmol/1 ± 27.88 S.D., 
serum phenoharbitone was 146.68 pmol/1 ^ 51.48 S.D., and 
serum primidone concentration was 46.09 pmol/1 t 21.02
S.D. There was no significant correlation between the 
serum phenytoin and the serum.folate concentrations, 
or indeed the phenoharbitone and primidone. The serum 
folate levels in patients taking phenytoin had a mean of 
1.78 pg/l ± 0.45 S.D., compared with 1.99 - 0.97 pg/1 
in patients who did not have phenytoin as part of their 
anticonvulsant medication and there v/as no significant 
difference between the two using Student's t test.
DISCUSSION
It seems that the group of epileptic patients 
studied were similar to what other workers have reported, 
and the low serum and CSF folate levels were almost uni­
versal. Folates are important in various aspects of 
intracellular metabolism, acting as a methyl donor, and 
are essential in nucleic acid synthesis (Norris and 
Pratt/...
Fig, 6.1 Correlation between serum and CSF folate 
pg/1 in 17 patients. No significant 
correlation.
Serum  Folate jug/1
n=17
N.S.
Cerebro-Spinal Fluid Folate jug/l
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Pratt, 1974). In the patients examined, low serum 
folate was found in 90.3% of the patients and this is 
comparable to the findings of other workers, although 
a significantly lower serum folate was found in patients 
taking phenytoin as part of their anticonvulsant therapy 
than in those who were on other anticonvulsants (Chapter 
3); in this study, the mean serum folate in patients 
on phenytoin was slightly lower, but this difference 
was not significant. The reason for this may be the 
larger group of patients examined in Chapter 3.
Folic acid has been shown to have convulsive 
properties on its own and antagonises the action of 
phenytoin in the rat (Hommes and Obbens, 1972), In 
addition, various reports were published on the effect 
of folic acid therapy on the seizure frequency and mental 
state of folate deficient epileptics. Worsening of 
seizure frequency was reported in 30% of 26 patients 
(Reynolds and Wales, 1967; Wells, I968), However, 
more recent reports have not confirmed this finding and 
folate therapy was reported to have no significant effect 
on the seizure frequency or mental state of the patient 
(Jensen and Olesen, 1970; Mattson, Gallagher, Reynolds 
and Glass, 1973). In this study, the patients in whom 
CSF folate was measured showed a reduction in the CSF 
values when compared to previous reports on CSF folate 
levels in patients with other neurological disease 
(Wells/,..
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(Wells and Casey, 1967). The CSF folate did, not 
correlate with serum folate as was reported previously 
(Wells and Casey, 1967) probably because the patients 
who had CSF folate examinations in this study were 
those with the lowest serum folate in the group and the 
differences between CSF folate levels were more than 
those of the serum. The serum anticonvulsants in the 
patients examined had means which were within the sor- 
called therapeutic levels for each drug, indicating that 
compliance of the patients examined was quite satisfactory,
The cause of folate deficiency in patients on anti­
convulsants is still unknown. However, an effect on 
the conversion of folic acid to 5-methyltetrahydrofolate 
has been hypothesised and it has been reported that CSF 
folate levels do not show a significant increase after 
folic acid therapy, but there is a significant increase 
when the reduced form of folic acid (3-formyltetrahydro- 
folate)is used (Mattson et al.. 1973).
The effects of treatment of folate deficient 
epileptics with folic acid and 5-formyltetrahydrofolate 
will be discussed in the next chapter.
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SUMMARY
1. Fifty™two adult epileptic patients had their serum 
folate examined; in 20 of them who showed the 
lowest serum folate levels, lumbar punctures were 
performed and the CSF folate was estimated.
2. A large percentage (90%) had reduced serum folate 
levels. CSF folate was reduced as well and the 
serum : CSF ratio was 1 ; 4.8.
3* Serum and CSF folate did not show a significant 
correlation.
/
4. The degree of reduction in serum folate was
more in patients who were on, among other drugs, 
phenytoin, but the difference between them and 
those who were on drugs other than phenytoin was 
not statistically significant.
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CHAPTER 7
Effects of treatment with folic acid or 5-formyl- 
tetrahydrofolate on serum and CSF folate and on CSF amine 
metabolites in epileptic patients,
INTRODUCTION
»
Treatment of epileptic patients who have low serum 
and CSF folate with folic acid was reported not to increase 
the CSF folate levels, while the levels increased when 
3-formyltetrahydrofolate (Leucovorin) was used (Mattson, 
Gallagher, Reynolds and Glass, 1973). The reason postul­
ated was that the anticonvulsant could be interfering with 
the conversion of folic acid to the active reduced form 
(3-methyltetrahydrofolate), a form which enters the CSF, 
hence preventing its entry to the CSF (Levitt, Nixon,
Pincus and Bertino, 1971). In addition, phenytoin and 
phenoharbitone serum and CSF concentrations were reported 
to be reduced during folic acid treatment, especially 
phenoharbitone (Mattson et al,, 1973). Cerebrospinal 
fluid amine metabolites, i.e. 5-hydroxy-3~indole acetic 
acid (HIAA) and possibly homovanilic acid (HVA), were 
reported to have higher concentrations in epileptic 
patients on anticonvulsant therapy, especially for HIAA 
in patients with high levels of serum anticonvulsants 
(Chadwick, Jenner and Reynolds, 1975), and it was thought 
that/...
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that reduced CSF folate might have some correlation 
with the increased levels of the amine metabolites 
(Reynolds, Chadwick, Jenner and Chanarin, 1975). This 
possibility of correlating folate with catecholamine and 
indolamine metabolism has been put forward because of 
reports on the existence in several species of a brain 
methyltransferase requiring 5-methyltetrahydrofolate as a 
methyl donor and capable of N-methylation of nearly .all 
primary or secondary catecholamines or indoleamines to 
vitro (Lauduron, 1972; ^eyson and Lauduron, 1974).
In this study, the CSF amine metabolites were 
measured before and after treatment with either folic 
acid or 5-formyltetrahydrofolate as they have been 
reported to be increased especially for HIAA in drug 
treated epileptic patients (Reynolds et al.. 1975), and 
it was interesting to find whether treatment with either 
folic acid or 5-formyltetrahydrofolate would affect their 
levels and whether or not this has any relevance to their 
epilepsy control,
METHODS
Seventeen patients were studied. They were eight 
females and nine males, age range 20-71 years (mean 40 
years). They were on multiple anticonvulsant drug 
therapy, including phenytoin, phenoharbitone, primidone 
in/...
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in various combinations, in addition to carbamazepine, 
sodium valproate, clonazepam and ethotoin. All the 
patients had been on anticonvulsants for at least 10 years.
Cerebrospinal fluid was obtained,within one hour of 
awakening in the morning, by lumbar puncture and blood 
samples were taken at the same time.
In the CSF, folate was measured in all the patients 
by the Lactobacillus Casei method, but successful HVA and 
HIAA measurements were done in only seven patients before 
and after treatment with either folic acid or 5-formyl- 
tetrahydrofolate. Cerebrospinal fluid HVA and HIAA were 
measured by fluorimetry.
The patients were divided into two groups. The first 
group, consisting of nine patients, were started on 3 mg 
of 5-forrayltetrahydrofolate intramuscularly daily for 
four weeks; in only four of them the CSF HVA and HIAA 
were estimated before and after the end of the treatment 
period. The second group, consisting of eight patients, 
were started on folic acid 5 mg t.i.d. for four weeks; in 
this group CSF HVA and HIAA were measured in only three 
patients before and after the treatment period.
Serum anticonvulsants, including phenytoin, pheno- 
barbitone and primidone, were measured by gas chromato­
graphy in all patients before and after the end of the 
treatment/...
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treatment periods, and the dose of the anticonvulsants 
was kept constant for three months before and three months 
after the four week treatment period. The measurements 
were repeated three months after the end of the treatment 
period.
For details of the techniques used see under METHODS.
Seizure frequency was recorded as major and raiiior 
seizures (see Chapter 1).
RESULTS
Serum folate
The results of the serum folate levels for the nine 
patients in the group which started on 5-formyltetrahydro™ 
folate had a mean of 1.58 pg/l ± 0.42 S.D. The levels 
increased after four weeks of treatment to a mean of 
10.7 pg/1 1 3.65 S.D. In the second group,which started 
on folic acid treatment, the serum folate in eight patients, 
before the treatment started, had a mean of 1.28 pg/1 ±
0.64 S.D., and it increased to 11.36 pg/1 1 3.5 S.D, There 
was no significant difference between the post-treatment 
folate levels in the two groups.
Cerebrospinal fluid folate levels
In the first group, i.e. the nine patients who had
5/...
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5-formyltetrahydrofolate, the CSF folate increased from 
8*88 pg/1 ± 4 S.D. to 41.66 pg/1 ± 7.3 S.D. In the group 
who had folic acid treatment, the CSF folate similarly 
increased from a mean of 8.27 pg/1 - 3.8 S.D, to 31.6 pg/1 
t 10.7 S.D. However, the post-treatment CSF folate levels 
showed a significant difference. The group who were on 
5-formyltetrahydrofolate had the highest increase (t = 1.86 
P <0.025, using Student's t test).
The serum and CSF folate did not show a significant 
correlation in all of the patients before treatment. After 
treatment in the group who received 5-formyltetrahydro- 
folate, there was a significant correlation (y = 1.69% + 
23.46; P<0.01) (Fig. 7.1). However, in the group who
had folic acid treatment, the correlation between serum 
and CSF folate levels remained insignificant.
The number of seizures/patient/month for the three 
months before treatment with either substance, during the 
month of actual therapy and for three months after the 
end of therapy did not show any significant difference in 
either group using Wilcoxon signed-ranks test (Fig. 7.2).
Cerebrospinal fluid HVA and HIAA
Both HVA and HIAA were measured successfully before 
and after treatment in both groups in only seven patients 
and/...
Fig. 7.1 Serum and CSF folate in pg/1, in nine
previously folate deficient patients. The 
patients had four weeks treatment with 5- 
formyltetrahydrofolate, y = 1.69% + 23.46 
(P<0.01).
/
Serum Folate jjg /l
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C erebro-Spinal Fluid Folate jug/l
Fig, 7.2 Number of seizures/patient/month. During 
the three months before starting treatment, 
in the treatment month, and for three months 
after the end of the treatment. Both groups 
showed no significant change, using Wilcoxon 
signed-ranlts test.
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Fig. 7.3 Correlation between CSF HVA and HIAA in
seven folate deficient epileptic patients 
before start of therapy, y = 0.0009 + 0.53%, 
t = 0.86 (P<0.02).
Fig. 7.4 Cerebrospinal fluid HIAA and HVA in patients 
on 3-formyltetrahydrofolate (— ), and folic
acid (---). Values before (©) and after (A)
treatment.
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and the main difficulty was obtaining enough CSF for the 
assay. Four of the patients were in the group which 
received 5-formyltetrahydrofolate and three were in the 
group which was treated with folic acid. There was no 
difference between the two groups prior to treatment and 
the correlation between HIAA and HVA is shovm in Fig. 7.3* 
After treatment, both HVA and HIAA were reduced in all 
four patients who were on 5-formyltetrahydrofolate,.but 
those who were on folic acid did not show a consistent 
change. The CSF HIAA in the four patients before treat­
ment with 5-formyltetrahydrofolate was 0.127 pmol/1 ±
0.02 S.D., and it was reduced after treatment to 0.045 pmol/1 
± 0.056 S.D. (P<0.01, using Student's ^  test). CSF 
HVA before treatment was 0.225 pmol/1 ± 0.04-7 S.D., and it 
was reduced to 0.142 pmol/1 ± 0.042 S.D. (P<0.05r using 
Student's t test). All results for both groups are shown 
in Fig. 7.4.
Serum anticonvulsant levels
Table 7.1 shows the results, mean ± S.D., of serum 
phenytoin, phenoharbitone and primidone concentrations in 
both groups of patients. The only significant change was 
in patients who received 5-formyltetrahydrofolate; there 
was a significant reduction in serum phenytoin level 
immediately after the end of the four week treatment period 
(P<0.05s using Student's t test). The serum phenytoin was 
similarly/...
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similarly reduced in the group that received folic acid, 
but this was not statistically significant. There was a 
trend for the serum phenoharbitone levels both in patients 
who were on the drug itself and those who were on primidone 
to increase whether they were treated with 5-formyltetra­
hydrofolate or with folic acid. However, this was not 
statistically significant.
*
DISCUSSION
The effects of botH folic acid and 5-formyltetra­
hydrofolate on the serum folate levels did not show any 
difference, as was expected. One of the main points 
behind this work was to see how much treatment with folic 
acid or 5-formyltetrahydrofolate would affect the CSF 
folate concentration.. Treatment of folate deficient 
epileptic patients with folic acid has been reported not 
to increase the CSF folate concentration to the normal 
levels. However, this was readily achieved when the 
reduced form, 5-formyltetrahydrofolate, was used, and it 
was presumed that the anticonvulsant drug interfered with 
conversion of folic acid to 5-methyltetrahydrofolate 
(Mattson et al., 1975). This supports the findings in 
this study in that the CSF folate, after four weeks of 
treatment with both folic acid and 5-formyltetrahydrofolate, 
increased, but the increase with the latter was more, and 
the/...
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the difference between the two was statistically signifi­
cant, This may indicate that there is indeed an effect 
by the anticonvulsant on the conversion of folic acid to 
5-methyltetrahydrofolate. The CSF levels of intravenously 
injected radioactive folic acid, 5-formyltetrahydrofolate 
and 5-methyltetrahydrofolate have been reported to show 
that only 5-methyltetrahydrofolate was transported through 
to the CSF (Levitt et al.. 1971). These authors al^o 
showed that administration of phenytoin did not interfere 
with this mechanism. In this study, 5-formyltetrahydro­
folate was used and it has previously been shown to be 
readily converted to 5-methyltetrahydrofolate (Nixon and 
Bertino, 1972). The serum and CSF folate before starting 
treatment did not show a significant correlation, most 
likely because the patients chosen for CSF folate estima­
tion were those who had the lowest serum folate levels 
(Chapter 6). After treatment, the group who received 
5-formyltetrahydrofolate showed a significant correlation, 
indicating a return to the normal distribution of folate 
in both blood and CSF (Reynolds, Gallagher, Mattson,
Bowers and Johnson, 1972). However, the group who received 
folic acid failed to show this return to normal correlation, 
therefore indicating an interference in the conversion of 
folic acid to 5-methyltetrahydrofolate.
There have been several reports on the effects of 
folate/...
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folate treatment on the seizure control in folate 
deficient epileptic patients. Worsening of seizure 
control has been reported (Reynolds and Wales, 1967). 
However, later reports did not substantiate this (Jensen 
and Olesen, 1970; Norris and Pratt, 1971), and the 
latter finding is consistent with results in this study. 
Folic acid treatment was noted to reduce serum phenytoin 
concentration (Jensen and Olesen, 1970; Mattson et.al*, 
1973). In this study, there was a significant reduction 
in the serum phenytoin concentration in those patients 
who received 3-formyltetrahydrofolate although there was 
a reduction with folic acid treatment, but this has 
failed to reach significance. The explanation of this 
is not yet clear and the previous suggestion of an increase 
in para-hydroxilation of phenytoin still needs to be 
investigated (Kutt, Winter and McDowell, 1966). The 
reduction in the serum phenytoin concentration being more 
significant when the reduced form of folate was used, 
supports the idea that phenytoin prevents the conversion 
of folic acid to 5-methyltetr^ahydrofolate and thereby the 
reduction in serum phenytoin concentration is less pro­
nounced when folic acid is used rather than 5-formyltetra- 
hydrofolate.
Folic acid when given by mouth has been shown to 
reduce cerebrospinal fluid KVA and to a less extent HIAA. 
This/*..
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This effect was less marked in patients on anticonvulsants 
(Hunter, Barnes, Curzon, Kantamaneni and Duncan, 1971)*
CSF amine metabolites have been reported to be raised in 
epileptic patients when compared to untreated epileptics 
and controls (Chadwick, Jenner and Reynolds, 1975). 
Cerebral amine metabolism has been linked, especially that 
of 5“hydroxytreptophone, to anticonvulsant drug effect 
(Meyer and Frey, 1973). However, the results shown.in 
this study point to the reduction of CSF HIAA and HVA 
after increasing the serum folate with 3-formyltetrahydro- 
folate. This is perhaps very important because it may 
indicate that the CSF amine metabolites are not related 
to the serum anticonvulsant level directly as has been 
suggested (Chadwick et al *. 1975), but indirectly through 
folate depletion, and the idea that there is an exit 
block to the amine metabolites may be true,on the assump­
tion that folate acts as a methyl donor in indoleamine 
metabolism (Korevaar, Geyer, Knap, Hsu and Mandell, 1973). 
This hypothesis of blocked exit has previously been 
suggested (Chadwick et al., 1975) and it has been shown 
that intraverticularly injected 5HIAA is retained for a 
longer time in rats receiving anticonvulsants (Chase,
Katz and Kopin, 1969).
The reduction of CSF HIAA and HVA with treatment on 
the one hand and the maintenance of the same seizure 
frequency/...
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frequency on the other may lead to the conclusion that 
the dependence of anticonvulsant drug action on central 
amines, which has been reported previously in mice, has 
a less effective role in humans (Meyer and Frey, 1973).
It seems possible that the relation of anticonvulsant 
effect on central amine metabolism is through its effects 
on folate. Although the number of patients studied was
à
small, the results were in agreement with other workers. 
However, the new finding of reduction of CSF amines and 
its implication as regards the role of folate in cate­
cholamine and indoleamine metabolism need further confirm­
ation.
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SUMMARY
1, Seventeen folate deficient epileptic patients were 
divided into two groups, and treated with either 
folic acid or its reduced form, 5-formyltetrahydro- 
folate, for a period of four weeks.
2. Serum folate increased after treatment with both* 
substances, but the CSF folate increased more 
significantly when the reduced form was used, 
indicating that the anticonvulsant may hinder the 
conversion of folic acid to 5-methyltetrahydrofolate.
3* Serum phenytoin levels were significantly reduced 
after treatment with 5-formyltetrahydrofolate.
t
4. Cerebrospinal fluid HIAA and HVA levels were reduced 
after treatment with 5-formyltetrahydrofdate, which 
may lead to the conclusion that there is an exit 
block in the central amine metabolism, secondary to 
folate depletion.
5. There was no effect on the seizure frequency in all 
the patients examined.
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SUGGESTIONS FOR FURTHER STUDY
It is evident from the summary of this thesis that 
there is a long way to go until an ideal anticonvulsant 
is available. However, any new drug which is added to 
the list of anticonvulsant agents needs close and 
continuous examination. I have tried to do this in the 
first section of this thesis, although in a limited way, 
i.e. by adding either drug to other medication. This 
may give some information as regards the interaction 
between drugs. It may also give information on their 
effectiveness as long as other parameters are kept 
constant. In this context, a study is needed where 
newly diagnosed epileptic patients receive only the 
trial drug, i.e. clonazepam or sodium valproate, as a 
sole anticonvulsant, thereby eliminating all possibilities 
of drug interactions, and the effects and side effects 
would be observed over a period of time.
The effect of sodium valproate on phenobarbitone 
metabolism needs further study. By giving patients,who 
are on phenobarbitone only, a large dose of sodium 
valproate, and studying the serum and urinary levels of 
phenobarbitone, one could try to establish where sodium 
valproate acts, whether it is in the absoi'p>tion, hepatic 
metabolism, or in the excretion of the drug.
The relation between reduced serum IgA levels 
during/...
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during phenytoin therapy and the HLA system needs 
confirmation. A larger number of patients is needed. 
However, it seems a fascinating idea that the immune 
system is affected by drugs in only susceptible 
individuals who possess certain genetic markers. The 
implications of this as regards predisposition to 
disease may be explored further.
The role of brain amine metabolites during drug 
treatment of epilepsy does not seem to be fully investi­
gated yet. The number of patients in this thesis is 
small, but there was no striking change in their 
seizure frequency. This may perhaps lead to the con­
clusion that brain amines, which were reduced when 5- 
formyltetrahydrofolate was given, do not play a major 
role in the anticonvulsant action of the anti-epileptic 
agents. This needs further investigation by treating 
a larger number of patients and observing any change in 
their seizure frequency after reducing their brain amines.
Finally, I feel strongly that the search for the 
ideal anticonvulsant should be one of the main targets 
of research. I hope that man will be the victor in the 
end.
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